Study of combined radiation and immunotherapy for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with pancreatic cancer that is locally advanced (has not spread to other organs) and is in the head, neck, or body of the pancreas.
- You have not had chemotherapy, radiation, or immunotherapy (like PD-1/PD-L1 drugs) for this cancer before.
- You are in generally good health, with a life expectancy of at least 3 months and are able to care for yourself (ECOG score 0-1).
- You must have adequate kidney, liver, and heart function, and normal blood counts.
- You cannot be pregnant or breastfeeding, and must not have had another cancer (except cured skin or early cervical cancer) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs (targeting CD40 and other immune cells) as a maintenance treatment for people with advanced pancreatic cancer that has not grown or has shrunk after initial chemotherapy. The goal is to see if this approach can keep the cancer from progressing longer.
This study tests a new combination of two drugs for advanced pancreatic cancer. It aims to see if adding an immunotherapy drug (which helps your immune system attack cancer) to standard chemotherapy can help control the cancer better.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial is testing two immunotherapy drugs (balstilimab and botensilimab) to see if they can shrink tumors in people with advanced pancreatic cancer that has worsened after at least one prior treatment. If you have microsatellite stable (MSS) disease, you may be eligible.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.